Oral premalignancies and squamous cell carcinoma

Clinics in Dermatology

Volumn 18, Issue 5, 2000, Pages 563-568

  Silverman Jr , Sol ^a   Sugerman, Philip B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BIOLOGICAL MARKER; DNA; EPIDERMAL GROWTH FACTOR; ONCOPROTEIN; PROTEIN P53; RETINOID; RETINOL; TOLONIUM CHLORIDE;

ALCOHOL CONSUMPTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; CIGARETTE SMOKING; EPITHELIUM DYSPLASIA; GENE MUTATION; HUMAN; KERATINOCYTE; LASER SURGERY; LEUKOPLAKIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; HUMANS; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 0034633112     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(00)00146-2     Document Type: Review

References (54)

1. Slaked lime and betel nut cancer in Papua New Guinea
2. Head and neck cancer
3. Field cancerisation of the oral cavity: Comparison of the spectrum of molecular alterations in cases presenting with both dysplastic and malignant lesions
4. The high-risk human papillomaviruses and oral cancer: Evidence for and against a causal relationship
5. p53 Mutations in human cancers
6. Loss of heterozygosity of p53 in oral cancers demonstrated by the polymerase chain reaction
7. Maintenance of identical p53 mutations throughout progression of squamous cell carcinoma of the tongue
8. p53 Gene mutations in oropharyngeal carcinomas: A comparison of solitary and multiple primary tumours and lymph-node metastases
9. Expression of p53 in oral mucosal hyperplasia, dysplasia and squamous cell carcinoma
10. p53 Expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma
11. p53 Expression in oral precancer as a marker for malignant potential
12. Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck
13. Immunohistochemical detection of p53 oncoprotein in human oral squamous cell carcinomas and leukoplakias: Comparison with proliferating cell nuclear antigen staining and correlation with clinicopathological findings
14. Association of overexpression of p53 oncoprotein with the state of cell proliferation in oral carcinoma
15. Oncogenes and tumor suppressor genes
16. The role of oncogenes, tumour suppressor genes and growth factors in oral squamous cell carcinoma: A case of apoptosis versus proliferation
17. Ras oncogene product expression in normal and malignant oral mucosa
18. Immunohistochemical detection of ras 21 in oral squamous cell carcinomas
19. Co-expression of ras p21 and epidermal growth factor receptor during various stages of tumour progression in oral mucosa
20. Immunohistochemical detection of the H-ras, K-ras, and N-ras oncogenes in squamous cell carcinoma of the head and neck
21. High incidence of H-ras oncogene mutations in squamous cell carcinoma of lip vermilion
22. Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinomas
23. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorgenesis
24. The erbB oncogenes as prognostic markers on oral squamous cell carcinomas
25. Increased expression of epidermal growth factor receptor in normal epithelium adjacent to head and neck carcinomas independent of tobacco and alcohol abuse
26. "Field cancerization" in oral stratified squamous epithelium: Clinical implications of multicentric origin
27. Multiple primary malignancies in head and neck cancer
28. Second respiratory and upper digestive tract cancer following oral squamous cell carcinoma
29. Incidence of multiple primary cancers. III. Cancers of the respiratory and upper digestive system as multiple primary cancers
30. Multiple primary cancer in patients with cancer of the head and neck: Second cancer of the head and neck, esophagus, and lung
31. Oral cancer: The behaviour and response to treatment of 194 cases
32. Field cancerisation in the head and neck
33. Survival rates in 548 patients with multiple neoplasma of the upper aerodigestive tract
34. Second malignant tumours in head and neck cancer
35. Multiple head and neck tumors: Evidence for a common clonal origin
36. Detection of field change in oral cancer using oral exfoliative cytology study
37. Evidence for field change in oral cancer based on cytokeratin expression
38. Molecular assessment of histopathological staging in squamous cell carcinoma of the head and neck
39. p53 expression: A potential biomarker for risk of multiple primary malignancies in the upper aerodigestive tract
40. Value of p53 expression in oral cancer and adjacent normal mucosa in relation to the occurrence of multiple primary carcinomas
41. Overexpression of p53 in normal oral mucosa of oral cancer patients does not necessarily predict further malignant disease
42. Angiogenesis in preneoplastic and neoplastic lesions
43. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients
44. Oral white lesions with special reference to precancerous and tobacco-related lesions: Conclusions of an international symposium held in Uppsala, Sweden, May 18-21, 1994
45. Diagnosis and management of leukoplakia and premalignant lesions
46. Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia
47. Oral epithelial dysplasia and the development of invasive squamous carcinoma
48. Leukoplakia, dysplasia, and malignant transformation
49. Early diagnosis of asymptomatic oral and oropharyngeal squamous cancers
50. Proliferative verrucous leukoplakia: A follow-up study of 54 cases
51. Sensitivity and specificity of OraScan toluidine blue mouthrinse in the detection of oral cancer and precancer
52. A review of the use of antioxidant supplements in the treatment of human oral leukoplakia
53. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer
54. Progress in improving diet to reduce cancer risk